Table 2.

Summary of glucose and glucagon concentrations

	4 to <8 years old			8 to <12 years old			12 to <17 years old
	IM	2 mg IN	3 mg IN	IM	2 mg IN	3 mg IN	IM	3 mg IN
N	6	12	12	6	11	12	12	12
Plasma glucose at nadir (mg/dL)a	71 ± 8	68 ± 9	67 ± 10	72 ± 12	75 ± 7	71 ± 6	69 ± 11	73 ± 9
Plasma glucose immediately prior to glucagon administration ≤70 mg/dL	3 (50)	6 (50)	7 (58)	1 (17)	3 (27)	6 (50)	7 (58)	1 (8)
≥25 mg/dL rise in glucose by 20 minc	6 (100)	11 (92)	12 (100)	6 (100)	11 (100)	12 (100)	12 (100)	12 (100)
Time until all participants experienced rise in glucose ≥25 mg/dL (min)d	10	20	15	20	20	15	20	20
Mean rise in plasma glucose at 20 min (mg/dL)	77 ± 10	60 ± 31	70 ± 20	49 ± 13	64 ± 11	67 ± 15	54 ± 14	41 ± 10
Maximum plasma glucose (mg/dL)b	211 ± 27	189 ± 54	208 ± 44	205 ± 24	201 ± 28	206 ± 32	194 ± 33	178 ± 27
Cmax glucagon (pg/mL)	6,343 ± 2,029	3,531 ± 1,762	4,033 ± 2,435	4,817 ± 3,086	2,952 ± 1,024	5,832 ± 2,106	4,382 ± 3,771	3,186 ± 2,294
Tmax glucagon (min)	17 (5, 30)	15 (10, 20)	17 (10, 60)	17 (5, 30)	15 (10, 20)	15 (10, 30)	17 (5, 30)	20 (15, 30)

Data are mean ± SD, n (%), or median (25th, 75th percentile). One participant completed only one of two scheduled dosing visits: a 10-year-old who withdrew from the study after the first dosing visit of 3 mg intranasal glucagon. C_max, peak central laboratory glucagon concentration; IM, intramuscular; IN, intranasal.

^aMinimum central laboratory glucose value measured within 10 min after glucagon administration;

^bmaximum glucose after administration of glucagon;

^cthe one participant who failed to achieve a ≥25 mg/dL rise in glucose blew his nose immediately after 2 mg intranasal dose administration and had a peak glucagon of only 324 pg/mL;

^dexcludes the one participant who blew his nose and did not experience a ≥25 mg/dL rise in glucose.